Literature DB >> 29232340

Ablative Therapies for Locally Advanced Pancreatic Cancer.

Rupen Shah1, Katherine T Ostapoff, Boris Kuvshinoff, Steven N Hochwald.   

Abstract

The vast majority of patients who present with pancreatic adenocarcinoma have locally advanced or metastatic disease at the time of presentation without possibility of cure. Although in recent years there have been some new promising chemotherapy regimens that improve overall survival by a few months, the prognosis remains dismal. There is, however, a subset of patients who experience durable stable disease or partial responses after initial courses of chemotherapy with locally advanced disease. In these select patients, there remains interest in local ablative therapy with or without resection as a means for local control, palliation of symptoms, and possible improved survival. This review describes the techniques, complications, and expected benefits of several ablative techniques as a treatment modality for locally advanced pancreatic cancer.

Entities:  

Mesh:

Year:  2018        PMID: 29232340     DOI: 10.1097/MPA.0000000000000948

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  3 in total

1.  Tissue-reactive drugs enable materials-free local depots.

Authors:  Sharda Pandit; Sandeep Palvai; Nicholas P Massaro; Joshua G Pierce; Yevgeny Brudno
Journal:  J Control Release       Date:  2022-01-22       Impact factor: 9.776

Review 2.  Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer.

Authors:  Stefano Lafranceschina; Oronzo Brunetti; Antonella Delvecchio; Maria Conticchio; Michele Ammendola; Giuseppe Currò; Tullio Piardi; Nicola de'Angelis; Nicola Silvestris; Riccardo Memeo
Journal:  Cancers (Basel)       Date:  2019-11-03       Impact factor: 6.639

3.  Laparoscopic ultrasonography-guided cryoablation of locally advanced pancreatic cancer: a preliminary report.

Authors:  Yingchun Wu; Yuqing Gu; Bin Zhang; Xin Zhou; Yanan Li; Zhuyin Qian
Journal:  Jpn J Radiol       Date:  2021-07-19       Impact factor: 2.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.